Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen's blockbuster multiple sclerosis therapy
Novartis' generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which is focusing on the use of artificial intelligence to track
Novartis may be planning to sell off its generics business Sandoz, but that hasn't stopped it investing in the unit ahead of a decision on its future later this year.
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit m
Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there are reports that a potential buyer has already come forward.
Switzerland's Social Democratic Party has argued that the government should step in and acquire Novartis' generics unit Sandoz if the company decides to sell it, according to local press re